Evaluation of Intralesional Verapamil Injection Efficacy in Peyronie's Disease

Document Type : Research Paper

Authors

1 Urologist & Fellowship of endo-urology

2 Professor of urology

3 professor of urology & fellowship of endo – urology

4 Postgraduate student of urology (urology resident)

Abstract

Introduction
 
To determine efficacy of intralesional injection of verapamil in improvement of symptoms and signs of peyronie's disease
 
Materials and Methods
 
In this study 27 patients were assessed of them 23 with single plaque of peyronie’s disease and the mean age of 50.2 years (21-72 years) underwent a total of 12 intralesional injection of verapamil. Before treatment, 16 patients (69.9 %) had pain, 23 patients (100%) penile induration, 19 patients (82.6%) penile curvature and 20 patients (86.9%) experienced erectile dysfunction. Then 3 months after injections, symptoms and signs of patients evaluated again.
 
Results
 
Pain resolved in 16 patients (100%), penile nodularity and chordea reduced in 18 (81%) and 14 patients (73.7%) respectively. Erectile dysfunction improved in 13 patients (65%). One patient (4.3%) found new penile nodularity in the opposite side of the initial nodule
 
Conclusion
 
Intralesional injection of verapamil is a simple and effective method in patients with peyronie's disease that have not responded to oral medication.

Keywords

References

1- Trost LW, Gur S, Hellstrom WJ. Pharmacological management of peyronie's disease. Drugs 2007; 67:527-545.
2- Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized doubleblind,
placebo-controlled study. Int J Impot Res 2004;16:238-243.
3- Fitch WP 3rd , Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical trifluoperazine, and topical
magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study. J Sex Med 2007; 4:477-
484.
4- Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a
double-blind study. J Urol 1993;149:56-58.
5- Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo
controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive
treatment for Peyronie's disease. J Urol 2006; 176:394.
6- Kelly RB. Pathways of protein secretion in eukaryotes. Science 1985; 230:25-32.
7- Levine LA, Estrad CR. Intralesional disease: a review verapamil for the treatment of Peyronie's. Int J Impot Res
2002; 14: 324-328.
8- Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol
1994; 151: 1522-1524.
9- Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of
three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology 2007; 69:950-954.
10 - Teloken C. Objective evaluation of non-surgical approach for Peyronie's disease. J Urol 1996; 155: 633A, abstract 1290.
11- Arena F, Peracchia G, Di Stefano C, Passari A, Larosa M, Cortellini P. Clinical effects of verapamil in the treatment
of Peyronie's disease]. Acta Biomed Ateneo Parmense 1995; 66:269-272.
12- Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term
single-blind study. Urology 1998; 51:620-626.
13 - Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997; 158:1395-1399.
14- Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease.
J Urol. 2002; 168:621-625; discussion 625-6 Department of Urology, Rush Presbyterian-St. Luke's Medical Center,
Chicago, Illinois, USA
15- Levine LA, Newell MM. FastSize Medical Extender for the treatment of Peyronie's disease. Expert Rev Med
Devices 2008 ;5:305-310.
16- Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's disease.
Urology 2007; 69:1181-1184.
17- Tunuguntla HS. Management of Peyronie's disease--a review. World J Urol 2001; 19:244-250.
18- Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy
of advanced and resistant Peyronie's disease: BJU Int 2002; 89:895-900.
19- Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's
disease: a double-blind, placebo controlled trial. J Urol 2007; 177:972-975. 
medical journal of mashhad university of medical sciences
Volume 53, Issue 2 - Serial Number 2
May and June 2009
Pages 84-89

Files

Share

How to cite

Statistics